Active substanceTsefpyromTsefpyrom
Similar drugsTo uncover
  • Isodep®
    powder w / m in / in 
       
  • Cephanorm
    powdersolution w / m in / in 
  •    
  • Dosage form: & nbsp
    powder for solution for intravenous and intramuscular administration

    Composition:

    Each vial contains

    Active substance: Tsefpyroma sulfate (in terms of cefpir) - 0.25 g, 0.5 g, 1.0 g, 2.0 g.

    Excipient: sodium carbonate anhydrous.

    Description:
    Crystalline powder white or white with a yellowish tint of color, with a weak specific odor. Hygroscopic.
    Pharmacotherapeutic group:Antibiotic-cephalosporin
    ATX: & nbsp

    J.01.D.E.02   Tsefpyrom

    Pharmacodynamics:

    Antibiotic from the group of cephalosporins of IV generation. It acts bactericidal, disrupting the synthesis of the cell wall of the microorganism. Has a wide spectrum of action against gram-positive and gram-negative bacteria, including strains resistant to aminoglycosides and / or cephalosporin antibiotics of the third generation. Highly resistant to the action of most beta-lactamases, within the bacterial cell, the molecular target is penicillin-binding proteins.

    It is active against: Acinetobacter spp., Citrobacter diversus, Citrobacter freundii, Clostridium perfringens, Enterobacter spp., Enterococcus faecalis, Enterococcus faecium, Escherichia coli, Hafhia alvei, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Moraxella catarrhalis, Morganella morganii, Neisseria spp. ., Peptostreptococcus spp., Proteus mirabilis, Proteus vulgaris, Providencia spp., Pseudomonas aeruginosa, Salmonella spp., Shigella spp., Serratia spp., Streptococcus spp., Staphylococcus spp.

    Pharmacokinetics:

    Cephpir is administered only parenterally.Penetrates into wound exudate, spinal fluid, female genital organs, prostate, kidneys, bronchial secretion, sputum and bronchial mucosa, peritoneal fluid, gallbladder tissue.

    It penetrates through the placental barrier, weakly into the breast milk. In therapeutic concentrations it is found in the blood and in most tissues and liquids for 12 hours after the administration. The kinetics of ceftpiroma concentration in the blood after intravenous and intramuscular injection is linear and depends on the dose administered. After repeated intravenous or intramuscular injection at an interval of 12 hours for 3-5 days, there was no cumulation of the drug and a change in the main pharmacokinetic parameters.

    Connection with plasma proteins - 10%. Half-life (T1/2) of cephirioma -1.8-2.2 hours. T1/2 cefpyroma and its total clearance are dose independent. The volume of distribution is 12-21 liters.

    In children, pronounced changes in the ketics of ceftirom are not observed.

    In the elderly, there may be changes in pharmacokinetics, the severity of which is related to the degree of impaired renal function. Correction of ceftpirium doses is necessary for creatinine clearance (CK) below 50 ml / min.

    It is not metabolized in the body, excreted by the kidneys (80-90%) and with bile.

    Indications:

    - Infectious-inflammatory diseases caused by drug-sensitive bacteria: sepsis / bacteremia;

    - complicated urinary system infections (including pyelonephritis, pyelitis, urethritis, cystitis);

    - respiratory tract infections (including pneumonia, lung abscess, pleural empyema);

    - skin and soft tissue infections, wound infections;

    - infections in patients with neutropenia.

    Contraindications:Hypersensitivity (including to other beta-lactam antibiotics), pregnancy, children under 12 years, lactation period.
    Carefully:Diseases of the gastrointestinal tract (including in the history: ulcerative colitis, regional enteritis or antibiotic-associated colitis), severe renal failure.
    Pregnancy and lactation:

    During pregnancy it is contraindicated.

    If you need to use the drug during lactation, breastfeeding should be discontinued.

    Dosing and Administration:

    Intravenous (jet or drip for 30 minutes) or intramuscularly.

    For intramuscular administration, the contents of the vial with 250 mg, 500 mg, 1000 mg of Isodep® are dissolved in 2 ml, 5 ml, 10 ml of water for injection, respectively.

    For intravenous fluid administration, the contents of the vial of 250 mg, 500 mg, 1000 mg or 2000 mg of Isodep® are dissolved in 2 ml, 5 ml, 10 ml or 20 ml of 0.9% sodium chloride solution, Ringer's solution, 5% dextrose solution, 5 % solution of fructose.

    For intravenous drip administration, 250 mg, 500 mg, 1000 mg or 2000 mg of the drug are dissolved respectively in 25 ml, 50 ml, 100 ml or 200 ml of 0.9% sodium chloride solution, Ringer's solution, 5% dextrose solution, 5% fructose solution.

    The daily dose is administered 2 times, with an interval of 12 hours.

    With infections of the urinary system, skin or soft tissues, the daily dose is 2 g (in severe cases, the dose may be increased to 4 g); with respiratory infections - 2-4 g; at a sepsis and infections against a background of a neutropenia - 4.

    The duration of treatment depends on the severity and characteristics of the course of the infectious process, the sensitivity of the microflora and is determined individually by the attending physician, usually 5-10 days.

    If the renal function is impaired, dose adjustment is performed depending on the QC. The first dose (initial) is 1-2 g, in the future, with KK 5-20 ml / min 0.5-1 g administered once a day; with KK 20-50 ml / min - 0.5-1 g 2 times a day. In patients on hemodialysis, the daily dose is 0.5-1 g; after each procedure of hemodialysis, add 0.25-0.5 g.

    Side effects:

    Local reactions: phlebitis, pain along the vein, soreness and infiltration at the site of intramuscular injection.

    Allergic reactions: urticaria, chills or fever, rash, itching, bronchospasm, eosinophilia, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), angioedema, anaphylactic shock.

    From the nervous system: headache, dizziness, encephalopathy.

    From the urinary system: disturbance of kidney function, oliguria, interstitial nephritis.

    From the digestive system: nausea, vomiting, diarrhea or constipation, flatulence, abdominal pain, dysbiosis, impaired liver function, candidal stomatitis and / or glossitis, pseudomembranous colitis.

    From the hematopoiesis: Hemolytic anemia, leukopenia, neutropenia, granulocytopenia, thrombocytopenia.

    From the cardiovascular system: potentially life-threatening arrhythmias after a rapid bolus injection into the central vein.

    Laboratory indicators: azotemia, increased urea concentration in the blood, increased activity of "liver" transaminases and alkaline phosphatase, hypercreatininemia, hyperbilirubinemia, Coombs positive reaction, hypocoagulation.

    Other: Superinfection (in particular, candidal vaginitis).

    Overdose:

    Symptoms: convulsions, encephalopathy (especially in patients with renal insufficiency), tremor, increased neuromuscular excitability.

    Treatment: symptomatic, hemodialysis.

    Interaction:

    Tsefpyre is pharmaceutically incompatible with other antibiotics, with a solution of sodium bicarbonate, with heparin and most other antimicrobial medicines.

    When used simultaneously with bactericidal antibiotics cephpie shows synergism, with bacteriostatic (macrolides, chloramphenicol, tetracyclines) - antagonism.

    Non-steroidal anti-inflammatory drugs, diuretics, aminoglycosides, polymyxin B, other drugs blocking tubular secretion inhibit the excretion of cephalosporins, increase their concentration in serum, extend T1/2, increase the risk of developing nephrotoxic reactions and bleeding.

    Tsefpyrom increases the effect of indirect anticoagulants.

    Special instructions:

    At the first introduction, the presence of a doctor is mandatory (the possibility of developing an anaphylactic reaction). In case of development of anaphylactic reactions, urgent therapy is performed (epinephrine, dopamine, electrolyte balance correction, oxygen therapy, antihistamines, glucocorticosteroids).

    Against the background of the introduction of ceftirom, it is necessary to take into account the possibility of developing pseudomembranous colitis, in case of its development, immediately stop the administration of the drug, prescribe the appropriate treatment (incl.vancomycin (inside) or metronidazole).

    When combined severe renal and hepatic insufficiency should regularly determine the concentration of the drug in the plasma (dose adjustment is performed depending on the CK).

    With long-term treatment, regular monitoring of peripheral blood (control of the number of leukocytes every 10 days), indicators of the functional state of the liver and kidneys is necessary.

    In case of mixed, aerobic-anaerobic infection before the identification of pathogens, it is advisable to add drugs that work against anaerobes.

    Effect on the ability to drive transp. cf. and fur:Not studied. Given the likelihood of side effects from the central nervous system, care should be taken when driving vehicles and working with mechanisms.
    Form release / dosage:
    Powder for the preparation of solution for intravenous and intramuscular injection 0.25 g, 0.5 g, 1.0 g or 2.0 g.
    Packaging:

    Powder for the preparation of solution for intravenous and intramuscular injection 0.25 g, 0.5 g, 1.0 g or 2.0 g of active substance in a bottle of clear, colorless glass type I with a butyl rubber rubber lid and a cap combined aluminum-plastic.

    1 The bottle together with the instruction for use is placed in a cardboard box. 10 packets are placed in a cardboard box (group packing).

    Storage conditions:
    In a dry, the dark place at a temperature of no higher than 20 ° C.
    Shelf life:
    2 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-000341
    Date of registration:22.02.2011 / 31.07.2014
    Expiration Date:22.02.2016
    Representation: & nbspInstitute of Health CJSCInstitute of Health CJSC
    Information update date: & nbsp23.10.2017
    Illustrated instructions
      Instructions
      Up